Welcome to our dedicated page for Korro Bio SEC filings (Ticker: KRRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Korro Bio, Inc. filings document the regulatory record of a biopharmaceutical company developing RNA-editing genetic medicines through its OPERA® platform. Its 8-K reports disclose operating and financial results, corporate presentations, clinical and regulatory program updates, capital-structure activity, and material events tied to its RNA-editing pipeline.
The company’s filings also cover proxy governance, executive compensation, equity incentive and inducement arrangements, employment agreements, and material collaboration and license agreements. Program-related disclosures focus on KRRO-121, hyperammonemia in urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research, alpha-1 antitrypsin deficiency, risk factors, and the financing and governance framework supporting Korro Bio’s development-stage operations.
KRRO filed a Form 144 reporting proposed sales of Common Stock. The filing lists sales by institutional holders including Atlas Venture Fund XI: 2,441 shares for $34,051.95 and Atlas Venture Opportunity Fund II: 419 shares for $5,845.05, each dated 05/28/2026. The filing also references a private placement dated 03/23/2023.
KRRO reports a proposed resale of 3,661 shares of Common Stock under a Form 144, with the notice dated 06/22/2026 and the securities listed for sale on Nasdaq. The filing notes these shares were originally issued in a Private Placement on 04/22/2024.
The excerpt also discloses recent dispositions: Atlas Venture Fund XI, L.P. sold 2,441 shares on 05/28/2026 for $34,051.95, and Atlas Venture Opportunity Fund II, L.P. sold 419 shares on 05/28/2026 for $5,845.05.
Korro Bio, Inc. Chief Operating Officer Todd Chappell reported the sale of 3,168 shares of common stock on June 16, 2026 at a weighted-average price of $10.83 per share. According to the disclosure, this was a mandatory sale solely to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units granted under the company’s 2023 Stock Option and Incentive Plan. After this tax-related sale, Chappell holds a total of 16,964 shares, which includes 10,066 shares underlying an RSU award scheduled to vest on December 15, 2026, subject to his continued service with the company.
Korro Bio, Inc. Chief Scientific Officer Vincent Loic A reported a sale of 3,418 shares of common stock at a weighted-average price of $10.83 per share. According to the disclosure, this was a mandatory sale solely to satisfy tax withholding obligations from vesting of a restricted stock unit granted under the 2023 Stock Option and Incentive Plan.
After this tax-related transaction, he holds 18,297 shares of common stock, including 10,858 shares issuable upon settlement of an RSU that is scheduled to vest on December 15, 2026, subject to continued service with the company.
Korro Bio, Inc. General Counsel Jeffrey Cerio reported an open-market sale of 6,609 shares of common stock at a weighted-average price of $10.83 per share. According to the filing, this was a mandatory sale solely to satisfy tax withholding obligations from vested restricted stock units under the 2023 equity plan.
After this transaction, Cerio holds 35,293 shares directly, including 20,951 shares underlying restricted stock units that are scheduled to vest on December 15, 2026, if his service with the company continues through that date.
Korro Bio, Inc. Senior Vice President of Finance Oliver Dolan reported an open-market sale of 3,383 shares of common stock on June 16, 2026 at a weighted-average price of $10.83 per share. According to the footnotes, this was a mandatory sale solely to cover tax withholding obligations arising from the vesting and settlement of restricted stock units (RSUs) granted under the company’s 2023 Stock Option and Incentive Plan.
After this transaction, Dolan holds 18,099 shares of common stock directly, which includes 10,741 shares issuable upon settlement of an RSU that is scheduled to vest on December 15, 2026, provided he maintains a continuous service relationship through that date.